First-in-Class Covalent PFKFB3 Inhibitors: Characterization in PDAC Models

A 398-byte dataset from figshare, last updated on 2026-05-26. It contains data related to the discovery and characterization of first-in-class covalent inhibitors targeting the kinase PFKFB3 in pancreatic ductal adenocarcinoma (PDAC) models. The dataset was authored by Alessandra Fiore and is shared under a CC-BY-NC-4.0 license.

Use Cases

• Analyze enzyme assay results for covalent binding and kinetic selectivity based on the described PFKFB3 inhibition.
• Evaluate drug combination synergy based on the described synergistic effects with standard chemotherapeutics.
• Assess cellular viability data across multiple PDAC cell lines as mentioned in the description.
• Study in vivo efficacy based on the described suppression of PDAC growth in zebrafish xenografts.

Strengths

• Data is associated with a peer-reviewed scientific discovery, confirming covalent binding via enzyme assays, mutagenesis, and mass spectrometry.
• The dataset is small (398.0 B), facilitating quick download and inspection.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The description notes limited cellular activity of the lead compound, which may restrict its use as a chemical probe.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from enzyme assays, cell viability tests, and zebrafish xenograft studies.

Freshness

Last updated 2026-05-26 06:14:42; freshness should be verified.